S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
Log in

NASDAQ:NOVN - Novan Stock Price, Forecast & News

$2.21
-0.03 (-1.34 %)
(As of 12/10/2019 04:00 PM ET)
Today's Range
$2.21
Now: $2.21
$2.37
50-Day Range
$1.96
MA: $2.17
$2.43
52-Week Range
$0.65
Now: $2.21
$3.02
Volume55,001 shs
Average Volume168,547 shs
Market Capitalization$59.04 million
P/E RatioN/A
Dividend YieldN/A
Beta1.85
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NOVN
CUSIPN/A
Phone919-485-8080

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.99 million
Book Value$0.20 per share

Profitability

Net Income$-12,670,000.00
Net Margins-348.29%

Miscellaneous

Employees47
Market Cap$59.04 million
Next Earnings Date3/25/2020 (Estimated)
OptionableNot Optionable

Receive NOVN News and Ratings via Email

Sign-up to receive the latest news and ratings for NOVN and its competitors with MarketBeat's FREE daily newsletter.


Novan (NASDAQ:NOVN) Frequently Asked Questions

What is Novan's stock symbol?

Novan trades on the NASDAQ under the ticker symbol "NOVN."

How were Novan's earnings last quarter?

Novan Inc (NASDAQ:NOVN) issued its earnings results on Friday, May, 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.24. The firm earned $0.10 million during the quarter, compared to the consensus estimate of $10.80 million. Novan had a negative return on equity of 2,070.25% and a negative net margin of 348.29%. View Novan's Earnings History.

When is Novan's next earnings date?

Novan is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Novan.

What price target have analysts set for NOVN?

2 Wall Street analysts have issued 1-year target prices for Novan's shares. Their forecasts range from $6.00 to $6.00. On average, they anticipate Novan's share price to reach $6.00 in the next year. This suggests a possible upside of 171.5% from the stock's current price. View Analyst Price Targets for Novan.

What is the consensus analysts' recommendation for Novan?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novan in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novan.

Has Novan been receiving favorable news coverage?

Media coverage about NOVN stock has been trending neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novan earned a coverage optimism score of 0.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Novan.

Are investors shorting Novan?

Novan saw a drop in short interest in the month of November. As of November 15th, there was short interest totalling 738,700 shares, a drop of 7.2% from the October 31st total of 796,400 shares. Based on an average trading volume of 59,000 shares, the short-interest ratio is currently 12.5 days. Approximately 4.5% of the company's shares are short sold. View Novan's Current Options Chain.

Who are some of Novan's key competitors?

What other stocks do shareholders of Novan own?

Who are Novan's key executives?

Novan's management team includes the folowing people:
  • Mr. G. Kelly Martin, CEO & Director (Age 60)
  • Ms. Paula Brown Stafford, Pres, COO & Director (Age 54)
  • Mr. John M. Gay, VP of Fin., Corp. Controller, Principal Financial Officer and Corp. Sec. (Age 42)
  • Dr. Nathan Stasko, Co-Founder & Chief Scientific Officer (Age 39)
  • Dr. Carri Geer, Sr. VP & CTO

When did Novan IPO?

(NOVN) raised $46 million in an initial public offering on Wednesday, September 21st 2016. The company issued 3,800,000 shares at $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Novan's major shareholders?

Novan's stock is owned by many different of retail and institutional investors. Top institutional investors include Prospera Financial Services Inc (0.37%), Millennium Management LLC (0.07%) and Virtu Financial LLC (0.05%). Company insiders that own Novan stock include G Kelly Martin, John M Gay, John W Palmour, Life Sciences Holdings L Malin, Paula B Stafford and Robert Alexander Ingram. View Institutional Ownership Trends for Novan.

Which major investors are buying Novan stock?

NOVN stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Virtu Financial LLC and Prospera Financial Services Inc. Company insiders that have bought Novan stock in the last two years include G Kelly Martin, John M Gay, John W Palmour, Paula B Stafford and Robert Alexander Ingram. View Insider Buying and Selling for Novan.

How do I buy shares of Novan?

Shares of NOVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novan's stock price today?

One share of NOVN stock can currently be purchased for approximately $2.21.

How big of a company is Novan?

Novan has a market capitalization of $59.04 million and generates $5.99 million in revenue each year. The company earns $-12,670,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. Novan employs 47 workers across the globe.View Additional Information About Novan.

What is Novan's official website?

The official website for Novan is http://www.novantherapeutics.com/.

How can I contact Novan?

Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company can be reached via phone at 919-485-8080 or via email at [email protected]


MarketBeat Community Rating for Novan (NASDAQ NOVN)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  183 (Vote Outperform)
Underperform Votes:  246 (Vote Underperform)
Total Votes:  429
MarketBeat's community ratings are surveys of what our community members think about Novan and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel